Mr Hopper has over 20 years experience in the management and funding of biotechnology and healthcare public companies with extensive capital markets experience in equity and debt raisings in Australia, Asia, US and Europe.
Mr Hopper’s sector experience has covered a number of therapeutic areas including anti-bacterials, medical devices, antibodies, inflammation and oncology, with a particular emphasis on cancer vaccines. Paul is Head of the Australia Desk and Head of the Life Sciences and Biotechnology practice at the Los Angeles merchant bank Cappello Group.
Mr Hopper has served on the boards of many listed biotechnology and healthcare companies, currently Imugene and Prescient Therapeutics. Previously he has served on the boards of Somnomed, Bone Medical, pSivida Corp, iSonea, and Advanced Biotherapy Inc.